ArticleEpilepsia2026
Incidence, mortality, and management of status epilepticus from 2012 to 2022: An 11-year nationwide study.
Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Incidence, mortality, and management of status epilepticus from 2012 to 2022: An 11-year nationwide study.Epilepsia · 2026Article
- Early Midazolam Infusion in Pediatric Status Epilepticus: Defining an Early Therapeutic Window for Seizure Control.Children (Basel, Switzerland) · 2025Article
- Alcohol use disorder and epileptogenesis in primary malignant brain tumors: temporal and tumor grade associations in a nationwide EHR cohort study.medRxiv : the preprint server for health sciences · 2025Article
- Propofol-related biological alterations and incidence of propofol infusion syndrome in status epilepticus: a 10-year cohort study.Frontiers in neurology · 2025Article
- Rethinking the classification of acute status epilepticus: structural brain vs. systemic etiologies.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveRecent data on status epilepticus (SE) incidence and mortality remain limited, despite the 2015 revision of its definition by the International League Against Epilepsy. The impact of the COVID-19 pandemic also remains unclear. We assessed trends in SE incidence, mortality, and management from 2012 to 2022 and examined the pandemic's impact.
methodsWe conducted a retrospective cohort study using the French National Health Data System, including all patients with a first hospitalization coded for SE (International Statistical Classification of Diseases, 10th Revision) from 2012 to 2022. Patients were stratified by intensive care unit (ICU) admission and mechanical ventilation (MV) duration. Annual age-standardized incidence rates were analyzed using Poisson regression. ICU admission rates, in-hospital mortality, and 1-year mortality were compared to 2019 (reference), adjusting for demographics, causes, and comorbidities. Interrupted time series analysis assessed changes during the pandemic.
resultsWe identified 118 050 patients hospitalized for first SE. From 2012 to 2019, the incidence of SE hospitalization decreased annually by 1.9%, from 18.0 to 15.6 per 100 000 (incidence rate ratio [IRR] = .981, 95% confidence interval [CI] = .978-.984). ICU hospitalizations declined similarly (from 10.4 to 9.59 per 100 000, IRR = .989, 95% CI = .986-.993), except among patients without MV. In-hospital mortality was 22.9% and 1-year mortality was 36.0% in 2019, stable compared to 2012. The highest mortality occurred in patients requiring prolonged MV or not admitted to ICU. During the COVID-19 years (2020-2022), SE hospitalizations dropped significantly (IRR = .897, 95% CI = .831-.969), ICU admission rates decreased, and mortality among non-ICU patients rose. SIGNIFICANCE: SE hospitalizations declined over the past decade, without a parallel reduction in mortality. The COVID-19 pandemic further disrupted SE care, with fewer hospitalizations, reduced ICU admissions, and increased mortality among non-ICU patients. Further research is needed to elucidate the factors driving declining incidence and excess mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.